SiemeisterG., SchirnerM., WeindelK., ReuschP., MenradA., MarmeD., Martiny-BaronG.: Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.Cancer Res, 59: 3185–3191, 1999.
4.
GraevenU., RodeckU., KarpinskiS., JostM., PhilippouS., SchmiegelW.: Modulation of angiogenesis and tumorigenicity of human melanocytiç cells by vascular endothelial growth factor and basic fibroblast growth factor.Cancer Res, 61: 7282–7290, 2001.
5.
HawighorstT., SkobeM., StreitM., HongY., VelascoP., BrownL., RiccardiL., Lange-AsschenfeldtB., DetmarM.: Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth, Am J Pathol, 160: 1381–1392, 2002.
6.
HanahanD., FolkmanJ.: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell, 86: 353–364, 1996.
7.
LippmanS.M., MatrisianL.M.: Protease inhibitors in oral carcinogenesis and chemoprevention.Clin Cancer Res, 6, 4599–4603, 2000.
8.
HerbstR., HidalgoM., PiersonA., HoldenS., BergenM., EckhardtS.: Angiogenesis inhibitors in clinical development for lung cancer.Semin Oncol, 29: 66–77, 2002.
9.
SemenzaG.: HIF-1: using two hands to flip the angiogenic switch.Cancer Metastasis Rev, 19: 59–65, 2000.
10.
FangJ., YanL., ShingY., MosesM.: HIF-1 alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis.Cancer Res, 61: 5731–5735, 2001.
11.
WedgeS., OgilvieD., DukesM., KendrewJ., CurwenJ., HennequinL., ThomasA., StokesE., CurryB., RichmondG.H., WadsworthP.F.: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.Cancer Res, 60: 970–975, 2000.
ArbiserJ., PetrosJ., KlafterR., GovindajaranB., McLaughlinE., BrownL., CohenC., MosesM., KilroyS., ArnoldR., LambethJ.: Reactive oxygen generated by Nox1 triggers the angiogenic switch.Proc Natl Acad Sci USA, 99: 715–720, 2002.
14.
TosettiF., FerrariN., De FloraS., AlbiniA.: Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents.FASEB J, 16: 2–14, 2002.
15.
DecensiA., BonanniB., Guerrieri-GonzagaA., TonisiR., ManettiL., RobertsonC., De PaloG., FormelliF., CostaA., VeronesiU.: Chemoprevention of breast cancer: the Italian experience.J Cell Biochem Suppl, 34: 84–96, 2000.
BenelliR., MoriniM., CarrozzinoF., FerrariN., MinghelliS., SantiL., CassatellaM., NoonanD.M., AlbiniA.: Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation.Faseb J, 16: 267–269, 2002.
